

PII: S0040-4039(96)01101-X

Synthesis of a Cyclic Urea as a Nonnatural Biopolymer Scaffold

Jong-Man Kim, Troy E. Wilson, Thea C. Norman, Peter G. Schultz*

Howard Hughes Medical Institute Department of Chemistry University of California Berkeley, CA 94720

Abstract: A cyclic urea trimer was synthesized from readily available amino acid derivatives using a simple, iterative approach. A selective amide reduction using borane (BH3-THF) and a triphosgenemediated cyclization are the key features in a synthesis of the cyclic urea trimer 2. Copyright © 1996 Elsevier Science Ltd

Peptides are attractive targets for drug discovery because of their high affinities and specificities toward biological receptors and the ease with which large peptide libraries can be synthesized in a combinatorial format. The screening of peptide libraries has led to the identification of numerous, biologically-active peptide leads.¹ However, the poor stability and bioavailibility of peptides *in vivo* have generally limited their therapeutic application.² One approach toward overcoming this obstacle has been the development of non-natural biopolymer scaffolds with improved pharmacological properties relative to peptides.³ As a part of our efforts to develop non-natural biopolymers, we have begun to investigate the synthesis of oligomeric cyclic ureas (1). Cyclic urea moieties are found in many biologically active compounds,⁴ and are expected to have greater membrane solubility and increased conformational rigidity relative to the corresponding linear urea. We now report a facile synthesis of the simple cyclic urea trimer 2 (R_1 = Me, R_2 = H, R_3 = Bn, R_4 = H, R_5 = Et).



An iterative approach was employed for the synthesis of the cyclic oligourea 2 (Scheme 1). Coupling of BOC-alanine *N*-hydroxysuccinimide ester 3 with benzylamine provided amide 4 in high yield (CH₂Cl₂, 25 °C, 18 h). Subsequent removal of the BOC protecting group (TFA, CH₂Cl₂, 25 °C, 1 h), amide reduction with BH₃-THF (THF, reflux, 22 h), and cyclization with triphosgene (CH₂Cl₂, 25 °C, 16 h) gave the cyclic urea 5.



Scheme 1.

Cyclic urea 5 was cleanly acylated in nearly quantitative yield by treatment with FMOC-glycine acid chloride 6^{5a} and the sterically hindered base 2,6-di-*t*-butyl-4-methylpyridine (CH₂Cl₂, 25 °C, 4 h). Similar reactions using diisopropylethylamine (DIEA) or triethylamine (TEA) resulted in a lower yield (< 50%) of 7, presumably because DIEA and TEA convert the acid chloride 6 into the less reactive oxazolone.^{5b} Removal of the FMOC protecting group with piperidine (CH₂Cl₂, 25 °C, 1 h), followed by reduction with borane BH₃-THF (THF, 60 °C, 3 h) and coupling with BOC-Phe-OSu (CH₂Cl₂, 25 °C, 1 h) provided 8. Proton and carbon NMR analysis of the crude mixture after work-up (1M HCl-MeOH, 25 °C, 1 h) indicated that the amide was cleanly reduced to the corresponding amine in the presence of the cyclic urea moiety. Reaction conditions used to convert 8 to the cyclic urea dimer 9 were similar to those employed to prepare the cyclic-urea 5 from 4 as shown in Scheme 1. Addition of another cyclic urea moiety to dimer 9 was achieved by repeating the reaction conditions from previous steps to afford trimer 2. All yields indicated represent isolated yields of pure intermediates and satisfactory spectroscopic and analytical data was obtained for all new compounds.⁶

In summary, we have described a simple, iterative method for the synthesis of the cyclic urea trimer 2 from readily available amino acid derivatives using a selective borane reduction and triphosgene promoted cyclization. Preliminary experiments on borane reduction and triphosgene cyclization have been promising, and efforts toward incorporating this chemistry into a solid-phase synthetic approach are currently underway.

Acknowledgment. We are grateful for financial support for this work from the Office of Naval Research (grant no. N00014-93-1-0380) and by the Director, Office of Energy Research, office of Basic Energy Sciences, Division of Material Sciences, and also by the Division of Energy Biosciences of the U.S. Department

of Energy under Contract No. DE-AC03-76SF00098. PGS is an Howard Hughes Medical Institute Investigator. JMK is an Howard Hughes Medical Institute Associate. TEW thanks the Howard Hughes Medical Institute and the Fannie and John Hertz Foundation for predoctoral fellowships.

References and Notes.

- (a) Lowe, G. Chem. Soc. Rev. 1995, 309. (b) Gallop, M.A.; Barret, R.W.; Dower, W.J.; Fodor, S.P.A.; Gordon, E.M. J. Med. Chem. 1994, 37, 1233. (c) Lam, K.S.; Salman, S.E.; Hersh, E.M.; Hruby, V.J.; Kazmierski, W.M.; Knapp, R.J. Nature, 1991, 354, 82 (d) Houghten, R.A.; Pinilla, C.; Blondelle, S.E.; Appel, J.R.; Dooley, C.T.; Cuervo, J.H. Nature 1991, 354, 84. (e) Fodor, S.P.A.; Read, J.L.; Pirrung, M.S.; Stryer, L.; Lu, A.T.; Solas, D. Science, 1991, 251, 767.
- Plattner, J.J.; Norbeck, D.W. In Drug Duscovery Technologies; Clark, C.R.; Moos, W.H. Eds.; Horwood: Chichester, 1990; pp 92-126.
- (a) For a recent review: Liskamp, R.M.J. Angew. Chem. Int. Ed. Eng. 1994, 33, 633. (b) Zuckermann, R.N.; Kerr, J.M.; Kent, S.B.H.; Moos, W.H. J. Am. Chem. Soc. 1992, 114, 10646. (c) Cho, C.Y.; Moran, E.J.; Cherry, S.R.; Stephans, J.; Fodor, S.P.A.; Adams, C.A.; Sundaram, A.; Jacobs, J.W.; Schultz, P.G. Science 1993, 261, 1303. (d) Burgess, K.; Linthicum, D.S.; Shin, H. Angew. Chem. Int. Ed. Engl. 1995, 34, 907.(e) Gennari, C.; Salom, B.; Potenza, D.; Williams, A. Angew. Chem. Int. Ed. Engl. 1994, 33, 2067. (f) Gennari, C.; Nestler, H.P.; Salom, B.; Still, W.C. Angew. Chem. Int. Ed. 1995, 34, 1763 and 1765.
- Lam, P.Y.S.; Jadhav, P.K.; Eyermann, C.J.; Hodge, C.N.; Ru, Y.; Bacheler, L.T.; Meek, J.L.; Otto, M.J.; Rayner, M.M.; Won, Y.N.; Chang, C.-H.; Weber, P.C.; Jackson, D.A.; Sharpe, T.R. Science, 1994, 263, 380.
- (a) Carpino, L.A.; Cohen, B.J.; Stephens, K.E.; Sadat-Aalaee, S.Y.; Tien, J.-H.; Langridge, D.C. J. Org. Chem. 1986, 51, 3734. (b) Carpino, L.A.; Chao, H.G.; Beyermann, M.; Bienert, M. J. Org. Chem. 1991, 56, 2635
- 6. ¹H NMR (400 or 500 MHz) and ¹³C NMR (70 MHz) were recorded on CDCl₃ solutions. Chemical shifts are reported in ppm relative to TMS or CHCl₃. Melting points (Pyrex capillary) are uncorrected. Compounds are oils unless melting points are specified.

4: white powder (mp: 100-102 °C); ¹H NMR 1.37 (d, J = 7.1 Hz, 3H), 1.40 (s, 9H), 4.23 (br s, 1H), 4.41 (br s, 2H), 5.20 (br s, 1H), 6.83 (br s, 1H), 7.25 (m, 5H); ¹³C NMR 18.4, 28.2, 43.3, 50.1, 80.0, 127.3, 127.5, 128.6, 138.1, 155.5, 172.6; FABMS m/z (relative intensity) 279 (M+1, 53), 223 (94), 179 (100), 106 (53); HRMS (FAB) m/z 279.1707 (C₁₅H₂₃N₂O₃ requires 279.1709)

5: white powder (mp: 82-84 °C); ¹H NMR 1.20 (d, J = 6.2 Hz, 3H), 2.83 (dd, J = 8.6, 6.4 Hz, 1H), 3.39 (t, J = 8.6 Hz, 1H), 3.75 (m, 1H), 4.35 (ABq, J = 15.0 Hz, 2H), 7.25 (m, 5H); ¹³C NMR 21.4, 45.4, 47.3, 51.6, 127.2, 127.9, 128.5, 137.1, 162.0; FABMS m/z (relative intensity) 191 (M+1, 100), 113 (9); HRMS (FAB) m/z 191.1186 ($C_{11}H_{15}N_2O_1$ requires 191.1184)

7: white powder (mp: 60-65 °C); ¹H NMR 1.31 (d, J = 6.4Hz, 3H), 2.88 (dd, J = 9.2, 2.5 Hz, 1H), 3.49 (t, J = 9.0Hz, 1H), 4.25-4.53 (m, 6H), 4.59 (dd, J = 19.1, 5.3 Hz, 1H), 4.68 (dd, J = 19.1, 5.7 Hz, 1H), 5.56 (br t, 1H), 7.26-7.43 (m, 9H), 7.64 (d, J = 7.3 Hz, 2H), 7.78 (d, J = 7.5 Hz, 2H); ¹³C NMR 20.0, 45.3, 47.1, 47.2, 47.5, 48.7, 67.0, 119.8, 125.1, 127.0, 127.6, 128.0, 128.1, 128.8, 135.4, 141.2,

143.8, 143.9, 154.0, 156.3, 169.2; FABMS m/z (relative intensity) 470 (M+1, 4), 248 (10), 231 (28), 191 (34), 179 (100), 165 (18), 133 (8); HRMS (FAB) m/z 470.2091 (C₂₈H₂₈N₃O₄ requires 470.2080)

8: white powder (mp: 40-45 °C); ¹H NMR 1.18 (d, J = 6.0 Hz, 3H), 1.38 (s, 9H), 2.72 (t, J = 8.3 Hz, 1H), 3.09 (br s, 1H), 3.10 (dd, J = 13.8, 6.2 Hz, 1H), 3.20-3.42 (m, 5H), 3.58 (m, 1H), 4.32 (ABq, J = 14.9 Hz, 2H), 4.38 (br s, 1H), 5.12 (d, J = 7.5 Hz, 1H), 6.90 (br s, 1H), 7.19-7.32 (m, 10H); ¹³C NMR 18.7, 28.2, 38.7, 39.2, 41.0 55.6, 79.7, 126.6, 127.4, 128.0, 128.4, 128.5, 129.3, 136.8, 136.9, 155.2, 161.4, 171.6; FABMS m/z (relative intensity) 481 (M+1, 14), 381 (100), 234 (59), 217 (52), 120 (50); HRMS (FAB) m/z 481.2823 (C₂₇H₃₇N₄O₄ requires 481.2815)

9: ¹H NMR 1.21 (d, J = 6.2 Hz, 3H), 2.69-2.77 (m, 2H), 2.85 (dd, J = 12.4, 5.6 Hz, 1H), 2.95-3.11 (m, 2H), 3.37 (t, J = 8.5 Hz, 1H), 3.48 (t, J = 8.6 Hz, 1H), 3.55 (dd, J = 8.6, 5.2 Hz, 1H), 3.65-3.90 (m, 4H), 4.34 (s, 1H), 4.38 (ABq, J = 15.1 Hz, 2H), 7.17-7.32 (m, 10H); ¹³C NMR 18.2, 38.0, 40.3, 41.8 47.6, 47.9, 49.6, 50.0, 51.1, 126.5, 127.1, 127.8, 128.4, 128.5, 129.1, 137.2, 137.3, 160.6, 161.3; FABMS m/z (relative intensity) 393 (M+1, 100), 301 (7), 217 (18), 203 (21), 117 (8); HRMS (FAB) m/z 393.2293 ($C_{23}H_{28}N_4O_2$ requires 393.2291)

10: ¹H NMR 1.21 (d, J = 6.1 Hz, 3H), 2.72 (m, 2H), 2.92 (m, 1H), 3.08 (m, 1H), 3.22 (d, J = 10.5 Hz, 1H), 3.30 (t, J = 9.0 Hz, 1H), 3.36 (t, 8.5 Hz, 1H), 3.50 (dd, J = 9.1, 2.0 Hz, 1H), 3.66-3.82 (m, 3H), 4.26 (t, J = 7.6 Hz, 2H), 4.41-4.62 (m, 5H), 5.63 (br t, 1H), 7.20-7.46 (m, 14H), 7.64 (d, J = 5.8 Hz, 2H), 7.76 (d, J = 7.5 Hz, 2H); 13C NMR 18.3, 37.9, 40.9, 45.3, 45.8, 47.1, 47.9, 50.0, 52.6, 67.0, 119.9, 125.1, 126.8, 127.0, 127.3, 127.6, 127.9, 128.5, 128.6, 129.7, 136.5, 137.1, 141.2, 143.9, 144.0, 154.4, 156.3, 160.6, 169.1; FABMS m/z (relative intensity) 672 (M+1, 56), 393 (24), 154 (100); HRMS (FAB) m/z 672.3187 ($C_{40}H_{42}N_5O_5$ requires 672.3186)

11: ¹H NMR 0.89 (t, J = 7.4 Hz, 3H), 1.20 (d, J = 6.1 Hz, 3H), 1.41 (s, 9H), 1.61 (m, 1H), 1.82 (m, 1H), 2.65 (dd, J = 13.2, 9.5 Hz, 1H), 2.71 (t, J = 8.1 Hz, 1H), 2.95-3.08 (m, 3H), 3.16-3.23 (m, 3H), 3.32-3.71 (m, 6H), 3.76-3.85 (m, 2H), 4.05 (m, 1H), 4.26 (d, J = 15.1 Hz, 1H), 4.44 (d, J = 15.1 Hz, 1H), 5.22 (br d, 1H), 7.10 (br s, 1H), 7.21-7.23 (m, 10H); ¹³C NMR 9.7, 18.3, 26.3, 28.3, 38.2, 39.0, 39.1, 41.1, 41.5, 47.9, 48.0, 50.2, 55.3, 55.6, 79.5, 126.7, 127.3, 127.9, 128.5, 128.7, 129.3, 136.7, 137.3, 155.4, 160.6, 161.4, 172.2; FABMS m/z (relative intensity) 621 (M+1, 7), 521 (100); HRMS (FAB) m/z 621.3748 (C₃₄H₄₉N₆O₅ requires 621.3764)

2: ¹H NMR 0.88 (t, J = 7.4 Hz, 3H), 1.19 (d, J = 6.1 Hz, 3H), 1.50 (m, 2H), 2.62 (dd, J = 13.2, 9.2 Hz, 1H), 2.69 (t, J = 8.0 Hz, 1H), 2.89-3.04 (m, 5H), 3.15 (t, J = 8.7 Hz, 1H), 3.28 (dd, J = 8.5, 6.1 Hz, 1H), 3.32-3.36 (m, 2H), 3.43 (t, J = 8.5 Hz, 1H), 3.52-3.86 (m, 6H), 3.98 (m, 1H), 4.24 (d, J = 15.1 Hz, 1H), 4.49 (d, J = 15.1 Hz, 1H), 4.62 (s, 1H), 7.21-7.32 (m, 10H); ¹³C NMR 9.5, 18.2, 28.5, 38.3, 38.6, 38.7, 40.6, 41.0, 47.7, 47.8, 48.0, 49.8, 50.2, 51.2, 53.4, 126.5, 127.2, 127.8, 128.5, 128.6, 129.4, 137.1, 137.4, 160.3, 160.6, 161.7; FABMS m/z (relative intensity) 533 (M+1, 100), 441 (20), 217 (36); HRMS (FAB) m/z 533.3235 (C₃₀H₄1N₆O₃ requires 533.3240)

(Received in USA 10 May 1996; accepted 30 May 1996)